GYRE THERAPEUTICS, INC. 8-K

What Happened
Gyre Therapeutics, Inc. (filed Item 7.01 Reg FD disclosure on March 12, 2026) reported remarks made at an investor conference on March 10, 2026. The company provided revenue and margin forecasts for its marketed and late‑stage assets and updates on Cullgen‑related development programs, including safety and dosing data for Cullgen’s TRK degrader (CG001419).

Key Details

• Gyre estimates potential liver fibrosis revenues for Hydronidone (F351) of approximately $400–$600 million within 5 years, based on patient population data.
• Gyre expects ETUARY® for lung fibrosis could sustain ~$100 million in revenue if no generic competitor enters the market in the near term.
• The company projects potential net margins of 20%–25% for commercial products and cited potentially favorable R&D tax deductibility at its Beijing campus and Cullgen’s Shanghai campus (contingent on tax policy).
• Gyre noted possible upside for F351 from (a) off‑label MASH use in hepatology (~40% MASH mix reported in Hepatitis B practices) and (b) expanded rheumatology use via a lung fibrosis label; currently 30%–40% of its lung fibrosis revenue is from rheumatoid diseases (RA, lupus, scleroderma, dermatomyositis).
• Cullgen updates: Australian cohort validated safety for CG001419 at 400 mg (≈one‑third of MTD); U.S. Phase 2 pain trial is enrolling at doses expected to produce ~95% TRK degradation. Cullgen also reported degrader antibody conjugates (DACs) show ~10–100× potency vs. standalone degraders, about half its R&D headcount is focused on DAC conjugation, and it has picomolar DC50 compounds across multiple targets (including GSPT‑1).

Why It Matters
These presentation remarks provide investors company guidance on near‑term commercial potential (revenue and margin targets) and insight into development progress for a partnered degrader program (CG001419). The figures are forward‑looking estimates (Gyre filed standard cautionary language) and depend on clinical results, regulatory outcomes, competitive entry (e.g., generics), and tax policy. Investors should treat these as management projections, review the company’s SEC filings for risk disclosures, and monitor clinical and market developments that could affect realized revenues and margins.